US FDA Inspection Concludes at Rubicon Research Facility; Company Notes Procedural Observations
Rubicon Research Limited, formerly known as Rubicon Research Private Limited, has provided an update on the outcome of a recent inspection conducted by the United States Food and Drug Administration (US FDA) at its manufacturing facility in Pithampur, Madhya Pradesh.The US FDA carried out an unannounced inspection of the company’s facility located in Pithampur from Monday, June 29, 2026, to Friday, July 3, 2026. This marked the first such inspection at the site since Rubicon Research acquired the facility last year. The completion of the integration process, implementation of a quality management system, and regulatory filings initiated the requirement for this inspection.
Upon conclusion of the inspection, a Form 483 was issued to the company containing two observations. Management stated that these observations are procedural in nature and do not relate to data integrity. Rubicon Research expressed confidence in working closely with the regulator toward successfully concluding the evaluation in a timely manner.
The company remains confident regarding the future operations of the facility, maintaining its commitment to a deep-rooted quality and compliance culture. As previously guided in the Q4 FY2026 investor update, Rubicon Research anticipates ramping up commercial operations at the Pithampur facility starting from Q1 of calendar year 2027.
RUBICON Stock Price Movement
Shares of Rubicon Research Limited slipped by 4.52% on Friday, closing at ₹1312.1 amid a challenging session. The stock recorded a total traded volume of 325,907 shares during the market period.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.